A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer� NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest